Through a partnership with Merck, Samsung Bioepis adds to its portfolio of biosimilars available in Australia.
Samsung Bioepis, of Incheon, Republic of Korea, is reporting that its adalimumab biosimilar Hadlima has been launched in Australia. The agent references AbbVie’s Humira and is indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult and pediatric Crohn disease, ulcerative colitis, hidradenitis suppurativa, and plaque psoriasis.
“With the launch in Australia, Samsung Bioepis’ adalimumab is now available in 3 markets: Europe, Canada, and Australia,” the company said in a statement. Via a partnership with Biogen, Hadlima was originally launched in 2018 in Europe under the brand name Imraldi. It was made available in Canada in 2021 via a partnership with Merck, which is also assisting with the Australia launch.
Hadlima marks the third anti–tumor necrosis factor biosimilar Samsung Bioepis has launched in Australia. The others are etanercept (Brenzys) and infliximab (Renflexis) biosimilars, in 2016 and 2017, respectively.
Hadlima will be available on the Australian Pharmaceutical Benefits Scheme (PBS) starting April 1, 2021. The PBS subsidizes medicines for residents of Australia.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.